Dipropylamino compounds

Ropinirole, sold under the brand name Requip among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). It is taken by mouth.

Trifluralin is a common preëmergent selective herbicide, a dinitroaniline. With about used in the United States in 2001, and in 2012, it is one of the most widely used herbicides. Trifluralin is also used in Australia, New Zealand, Iran, India, Brazil and previously in the EU. Introduced in 1964, Trifluralin was the first organofluorine compound used as an agrochemical.

Dipropyltryptamine (DPT), also known as '''N,N-dipropyltryptamine or as "The Light'''", is a psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It is taken orally or by other routes.

8-OH-DPAT, also known as 8-hydroxy-2-(dipropylamino)tetralin, is a serotonin 5-HT1A receptor agonist of the 2-aminotetralin family which was developed in the 1980s and has been widely used to study the function of the 5-HT1A receptor. It was one of the first major 5-HT1A receptor full agonists to have been discovered.

Dipropylamine is an organic compound with the formula . It is classified as a secondary amine. It is a colorless liquid with a "fishy" odor. It is a precursor to various herbicides such as trifluralin, oryzalin, and vernolate. thumb|left|Trifluralin, an herbicide containing a dipropylamino group|110px

Alpidem, sold under the brand name Ananxyl, is a nonbenzodiazepine anxiolytic medication which was briefly used to treat anxiety disorders but is no longer marketed. It was previously marketed in France, but was discontinued due to liver toxicity. Alpidem is taken by mouth.

7-OH-DPAT is a synthetic compound that acts as a dopamine receptor agonist with reasonable selectivity for the D3 receptor subtype, and low affinity for serotonin receptors, unlike its structural isomer 8-OH-DPAT. 7-OH-DPAT is self-administered in several animal models, and is used to study its addiction effects to cocaine.

Oryzalin is a herbicide of the dinitroaniline class. It acts through the disruption (depolymerization) of microtubules, thus blocking anisotropic growth of plant cells. It can also be used to induce polyploidy in plants as an alternative to colchicine.

Proglumetacin (usually supplied as the maleate salt) is a nonsteroidal anti-inflammatory drug (NSAID). It is a codrug (that is, a mutual prodrug) of indometacin and proglumide. After oral intake, it is absorbed and metabolized to indometacin and proglumide. These two substances are then released into the system in a 1:1 molar ratio.

Proglumide, sold under the brand name Milid, is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application.

5-OH-DPAT is a synthetic compound that acts as a dopamine receptor agonist with selectivity for the D2 receptor and D3 receptor subtypes. Only the (S)-enantiomer is active as an agonist, with the (R)-enantiomer being a weak antagonist at D2 receptors. Radiolabelled 11C-5-OH-DPAT is used as an agonist radioligand for mapping the distribution and function of D2 and D3 receptors in the brain, and the drug is also being studied in the treatment of Parkinson's disease.

Prosulfocarb is a preëmergent herbicide used agriculturally in Australia, the EU, Japan, New Zealand, (since 2020), Morocco and Iran, for control of annual ryegrass and toad rush in wheat and barley crops. It was introduced to the EU in 1988 and is rapidly growing in use, with sales increasing by over 500% in France since 2008.

UH-301, also known as '(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin ((S)-5-FHDPAT'), is a drug and research chemical widely used in scientific studies. It acts as a selective serotonin 5-HT1A receptor silent antagonist. It is structurally related to 8-OH-DPAT. UH-301 was found to produce a head-twitch response in mice which is usually typical of 5-HT2A agonist drugs, and has subsequently been used to investigate how 5-HT1A receptor activity modulates 5-HT2A receptors downstream.

chemical compound

UH-232 ((+)-UH232) is a drug which acts as a subtype selective mixed agonist-antagonist for dopamine receptors, acting as a weak partial agonist at the D3 subtype, and an antagonist at D2Sh autoreceptors on dopaminergic nerve terminals. It causes dopamine release in the brain and has a stimulant effect, as well as blocking the behavioural effects of cocaine. It may also serve as a 5-HT2A receptor agonist, based on animal studies. It was investigated in clinical trials for the treatment of schizophrenia, but unexpectedly caused symptoms to become worse.

AFDX-384 (BIBN-161) is a drug which acts as a selective antagonist of the muscarinic acetylcholine receptors, with selectivity for the M2 and M4 subtypes. It is used mainly for mapping the distribution of M2 and M4 muscarinic receptors in the brain, and studying their involvement in the development and treatment of dementia and schizophrenia.

RDS-127, also known as '4,7-dimethoxy-N,N-dipropyl-2-aminoindane', is a drug of the 2-aminoindane family which is used in scientific research. It acts as a D2-like receptor agonist and also has some serotonin and adrenergic agonist effects, as well as some anticholinergic action, and produces both anorectic and pro-sexual effects in animal studies.

4-HO-DPT, also known as '4-hydroxy-N,N-dipropyltryptamine or as deprocin', is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally.

Ro48-6791 is a drug, an imidazobenzodiazepine derivative developed by Hoffman-LaRoche in the 1990s.

PNU-99,194(A) (or U-99,194(A)) is a drug of the 2-aminoindane family which acts as a moderately selective D3 receptor antagonist with ~15-30-fold preference for D3 over the D2 subtype. Though it has substantially greater preference for D3 over D2, the latter receptor does still play some role in its effects, as evidenced by the fact that PNU-99,194 weakly stimulates both prolactin secretion and striatal dopamine synthesis, actions it does not share with the more selective (100-fold) D3 receptor antagonists S-14,297 and GR-103,691.